Results 161 to 170 of about 3,103 (173)

2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis

Journal of Controlled Release, 2019
Fernanda Paola Pons-Faudoa, Antons Sizovs, Nicola Di Trani   +2 more
exaly  

Review of Synthetic Routes and Final Forms of Integrase Inhibitors Dolutegravir, Cabotegravir, and Bictegravir

Organic Process Research and Development, 2019
David L Hughes
exaly  

Cabotegravir/Rilpivirine/Testosterone

Reactions Weekly
openaire   +1 more source

Cabotegravir/rilpivirine (Cabenuva) for HIV-1 infection.

The Medical letter on drugs and therapeutics, 2021
openaire   +1 more source

Implementing long-acting injectable cabotegravir and rilpivirine in Africa

The Lancet Infectious Diseases
Chloe, Orkin, Kyle, Ring
openaire   +2 more sources

Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

Lancet Regional Health - Europe, The
Paul Thoueille, Eva Choong, Aline Munting   +2 more
exaly  

Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study

Clinical Infectious Diseases
Mattia Berton, Manuel Battegay, Catia Marzolini   +2 more
exaly  

Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV

Clinical Infectious Diseases
Angela Colbers, Lena van der Wekken
exaly  

Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

Antimicrobial Agents and Chemotherapy, 2017
exaly  

Cabotegravir - die Monatsspritze gegen HIV

Österreichische Apothekerzeitung, 2017
openaire   +1 more source